Cargando…
Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strateg...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600379/ https://www.ncbi.nlm.nih.gov/pubmed/37901223 http://dx.doi.org/10.3389/fimmu.2023.1256740 |
_version_ | 1785125978618462208 |
---|---|
author | Wang, Linlin Du, Changqi Jiang, Bing Chen, Lin Wang, Zibing |
author_facet | Wang, Linlin Du, Changqi Jiang, Bing Chen, Lin Wang, Zibing |
author_sort | Wang, Linlin |
collection | PubMed |
description | Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strategy to expand anti-PD-1/PD-L1-based immunotherapy is now a hot research topic. The conventional use of chemotherapeutic drugs and targeted drugs inevitably leads to resistance, toxic side effects and other problems. Recent research, however, suggests that by adjusting the dosage of drugs and blocking the activation of mutational mechanisms that depend on acquired resistance, it is possible to reduce toxic side effects, activate immune cells, and reshape the immune microenvironment of lung cancer. Here, we discuss the effects of different chemotherapeutic drugs and targeted drugs on the immune microenvironment. We explore the effects of adjusting the dosing sequence and timing, and the mechanisms of such responses, and show how the effectiveness and reliability of combined immunotherapy provide improved treatment outcomes. |
format | Online Article Text |
id | pubmed-10600379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106003792023-10-27 Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer Wang, Linlin Du, Changqi Jiang, Bing Chen, Lin Wang, Zibing Front Immunol Immunology Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strategy to expand anti-PD-1/PD-L1-based immunotherapy is now a hot research topic. The conventional use of chemotherapeutic drugs and targeted drugs inevitably leads to resistance, toxic side effects and other problems. Recent research, however, suggests that by adjusting the dosage of drugs and blocking the activation of mutational mechanisms that depend on acquired resistance, it is possible to reduce toxic side effects, activate immune cells, and reshape the immune microenvironment of lung cancer. Here, we discuss the effects of different chemotherapeutic drugs and targeted drugs on the immune microenvironment. We explore the effects of adjusting the dosing sequence and timing, and the mechanisms of such responses, and show how the effectiveness and reliability of combined immunotherapy provide improved treatment outcomes. Frontiers Media S.A. 2023-10-09 /pmc/articles/PMC10600379/ /pubmed/37901223 http://dx.doi.org/10.3389/fimmu.2023.1256740 Text en Copyright © 2023 Wang, Du, Jiang, Chen and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Linlin Du, Changqi Jiang, Bing Chen, Lin Wang, Zibing Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer |
title | Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer |
title_full | Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer |
title_fullStr | Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer |
title_full_unstemmed | Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer |
title_short | Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer |
title_sort | adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600379/ https://www.ncbi.nlm.nih.gov/pubmed/37901223 http://dx.doi.org/10.3389/fimmu.2023.1256740 |
work_keys_str_mv | AT wanglinlin adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer AT duchangqi adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer AT jiangbing adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer AT chenlin adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer AT wangzibing adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer |